|
|
|
Allos
Therapeutics, Inc. (NASDAQ: ALTH)
is a biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment of cancer. The company's
lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with
relapsed or refractory peripheral T-cell lymphoma. The company
is also investigating PDX in patients with non-small cell lung
cancer and a range of other lymphoma sub-types. The Company's other product candidate
is RH1, a targeted chemotherapeutic agent currently being evaluated
in a Phase 1 trial in patients with advanced solid
tumors or non-Hodgkins Lymphoma (NHL). more
|
|